Fate Therapeutics Inc
FATE
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
124.3% downsideOvervalued by 124.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $331.03 Million |
|---|---|
| Enterprise Value | $368.82 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.15 |
| Beta | 2.14 |
| Outstanding Shares | 120,030,638 |
Return
| Return on Equity | -72.29% |
|---|---|
| Return on Assets | -45.59% |
| Return on Invested Capital | -55.74% |
Valuation & Multiples
| P/E Ratio | -2.62 |
|---|---|
| PEG | 15.41 |
| Price to Sales | - |
| Price to Book Ratio | 2.22 |
| Enterprise Value to Revenue | 58.4 |
| Enterprise Value to EBIT | -2.6 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.43 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7341▼ 362.99% |
|---|---|
| Total Calls | 80,100▲ 220.40% |
| Total Puts | 58,800▼ 46.10% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 62.36%▲ 1.74% |
|---|---|
| Total Invested | $88.85M▲ 25.26% |
| Investors Holding | 159▲ 12.00% |
ESG Score
No data
About Fate Therapeutics Inc
CEO: William Rastetter Relevant Senate Committees
This committee controls taxation, trade, and entitlement spending (like Medicare). Tax policy directly impacts corporate profitability, and changes in Medicare pricing or reimbursement for biological products can significantly affect Fate Therapeutics' revenue streams and valuation.
This committee directly regulates the FDA and NIH, which are critical for biological product manufacturers like Fate Therapeutics. Its oversight of drug approval processes, research funding, and healthcare policy directly impacts the company's ability to develop, market, and commercialize its products.